Modality
Cell Therapy
MOA
EGFRi
Target
SHP2
Pathway
RNA Splicing
LNCRCCLL
Development Pipeline
Preclinical
Jan 2025
→ Jan 2031
PreclinicalCurrent
NCT05644638
1,842 pts·LN
2025-01→2031-01·Active
1,842 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-114.8y awayInterim· LN
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
Preclinical
Active
Catalysts
Interim
2031-01-11 · 4.8y away
LN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05644638 | Preclinical | LN | Active | 1842 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |